SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Tamarkin Dov (Last) (First) (Middle) C/O FOAMIX PHARMACEUTICALS LTD. 2 HOLTZMAN STREET (Street) REHOVOT L3 7670402 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/01/2018	3. Issuer Name and Ticker or Trading Symbol Foamix Pharmaceuticals Ltd. [ FOMX ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	2,563,489	I	See footnote(1)
Ordinary Shares	11,239	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	05/13/2014	05/13/2018	Ordinary Shares	2,094	$5.04	I	See footnote(1)
Options	(2)	12/29/2024	Ordinary Shares	24,000	$5.88	D
Options	(3)	12/29/2024	Ordinary Shares	45,000	$6.77	D
Options	(4)	03/01/2026	Ordinary Shares	100,000	$6.34	D
Restricted Share Units	(5)	(5)	Ordinary Shares	5,625	$0.00	D

Explanation of Responses:

1. Shares and Warrants held by Tamarkin Medical Innovation Ltd., an Israeli company controlled by Dr. Dov Tamarkin

2. The Options vested over a period of three years from December 29, 2014 (33.3% on each anniversary of such date) and ending December 29, 2017

3. Options vest over a period of four years from December 29, 2014 (25% on the first anniversary of such date and 6.25% every three months thereafter) and ending December 29, 2018

4. Options vest over a period of four years from March 1, 2016 (25% on the first anniversary of such date and 6.25% every three months thereafter) and ending March 1, 2020

5. The Restricted Share Units vest in equal installments every three months over the vesting period beginning October 15, 2017 and ending January 15, 2019.

Remarks:

The Reporting Person is filing this form in connection with the Issuer's transition from a foreign private issuer to a domestic issuer, effective January 1, 2018. Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Ilan Hadar as attorney-in-fact for Dov Tamarkin	01/11/2018
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.